Biotech giant Amgen (AMGN) spent most of the first half of this year stuck in the red zone of the SIA S&P 100 Index Report. Since August, however, it has been steadily making its way back up the relative strength rankings. Yesterday, after jumping 11 positions to 25th place, capping off a gain of 26 places in the last month, Amgen returned to the Green Favored Zone for the first time since December of 2022.
Menu